466 Combined inhibition of KRAS G12C and PD-1 boosts the therapeutic efficacy via conditioning of tumor microenvironment in pre-clinical humanized NSCLC mouse models

Abstract

BackgroundRAS is one of the most frequently mutated oncogenes in lung cancer. The KRAS G12C mutation is present in approximately 39% of KRAS-mutant NSCLC.1 Mutant KRAS is linked to PD-L1...